Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy.

Wee CC, Girotra S, Weinstein AR, Mittleman MA, Mukamal KJ.

J Am Coll Cardiol. 2008 Aug 19;52(8):620-5. doi: 10.1016/j.jacc.2008.05.021.

2.

Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.

Domanski M, Tian X, Fleg J, Coady S, Gosen C, Kirby R, Sachdev V, Knatterud G, Braunwald E.

Am J Cardiol. 2008 Oct 15;102(8):1023-7. doi: 10.1016/j.amjcard.2008.05.053. Epub 2008 Aug 9.

PMID:
18929703
3.

Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts.

Mukamal KJ, Girotra S, Mittleman MA.

Am Heart J. 2006 Feb;151(2):368-72.

PMID:
16442902
4.

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C.

Circulation. 2000 Jul 11;102(2):157-65.

5.

Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study.

Campeau L, Lespérance J, Bilodeau L, Fortier A, Guertin MC, Knatterud GL.

Angiology. 2005 Mar-Apr;56(2):191-9.

PMID:
15793608
7.

Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.

Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL.

J Am Coll Cardiol. 2000 Nov 15;36(6):1877-83.

8.

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.

White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML; Post Coronary Artery Bypass Graft Trial Investigators.

Circulation. 2001 Nov 27;104(22):2660-5.

9.

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, Geller N, Herd A, Hickey A, Hunninghake DB, Knatterud GL, White C.

Diabetes. 1999 Jun;48(6):1289-94.

PMID:
10342818
10.

Hematologic parameters, atherosclerotic progression, and prognosis in patients with previous coronary artery bypass grafting (from the Post CABG Trial).

Mukamal KJ, Wellenius GA, Mittleman MA.

Am J Cardiol. 2009 Feb 1;103(3):328-32. doi: 10.1016/j.amjcard.2008.09.080. Epub 2008 Nov 19.

PMID:
19166684
11.

Relation of heart rate response to exercise with prognosis and atherosclerotic progression after coronary artery bypass grafting.

Girotra S, Keelan M, Weinstein AR, Mittleman MA, Mukamal KJ.

Am J Cardiol. 2009 May 15;103(10):1386-90. doi: 10.1016/j.amjcard.2009.01.346. Epub 2009 Mar 25.

PMID:
19427433
12.

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.

Post Coronary Artery Bypass Graft Trial Investigators.

N Engl J Med. 1997 Jan 16;336(3):153-62. Erratum in: N Engl J Med 1997 Dec 18;337(25):1859.

13.

Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.

Makuuchi H, Furuse A, Endo M, Nakamura H, Daida H, Watanabe M, Ohashi Y, Hosoda Y, Hosoda S, Yamaguchi H, Yasui H.

Circ J. 2005 Jun;69(6):636-43.

14.

Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial.

Hunninghake DB.

Am J Cardiol. 1998 Nov 26;82(10B):45T-48T. Review.

PMID:
9860374
15.

Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.

Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC.

J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054.

16.

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y.

Circulation. 1999 Jun 29;99(25):3241-7.

17.
18.

Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety.

Kulik A, Ruel M.

Expert Opin Drug Saf. 2009 Sep;8(5):559-71. doi: 10.1517/14740330903188413. Review.

PMID:
19673591
19.

Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial.

Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M.

Ann Thorac Surg. 2011 Oct;92(4):1284-90; discussion 1290-1. doi: 10.1016/j.athoracsur.2011.04.107.

PMID:
21958773
20.

Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease.

Takamiya Y, Miura S, Kawamura A, Tanigawa H, Zhang B, Iwata A, Nishikawa H, Matsuo K, Shirai K, Saku K.

Coron Artery Dis. 2009 Jun;20(4):288-94. doi: 10.1097/MCA.0b013e32832c4538.

PMID:
19440067
Items per page

Supplemental Content

Write to the Help Desk